stockrow
Friday 6 November 2026
Export BNGO’s income statement to Excel — free account
Bionano Genomics, Inc.
BNGO Healthcare Medical Instruments & Supplies
Bionano Genomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.5 million, down 7.37% from fiscal 2024.
- Revenue
- +21.4%
- EPS
- +67.8%
- Free cash flow
- −33.9%
- Total debt
- −1.91%
Quarter to June 2026, against a year earlier
1.11
0.08
−6.72%
Follow BNGO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 7 | 10 | 12 | 10 | 9 | 18 | 28 | 36 | 31 | 29 | 30 | +17.3% | 32 | 43 | 55 | +24.3% | |
| Gross margin, % | 47.32 | 36.55 | 27.41 | 33.18 | 32.61 | 21.54 | 21.38 | 26.49 | 1.23 | 46.25 | 47.51 | (1.1) pt | ||||||
| EBT | (19) | (23) | (18) | (30) | (41) | (78) | (131) | (232) | (112) | (26) | (32) | +3.8% | ||||||
| EBT margin, % | (277.29) | (245.63) | (154.00) | (294.13) | (483.09) | (434.64) | (470.15) | (643.57) | (363.87) | (92.35) | (106.36) | +184.9 pt | ||||||
| Net income | (19) | (23) | (18) | (30) | (41) | (72) | (133) | (232) | (112) | (26) | (32) | +3.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 67,928.00 | 2,112.22 | 1,017.01 | 405.18 | 48.84 | 38.90 | 57.56 | 63.47 | 24.21 | 5.24 | 2.61 | (65.1%) | |||||
| Earnings | (187,102.70) | (5,180.02) | (1,562.87) | (1,191.62) | (233.53) | (155.69) | (275.45) | (407.78) | (88.13) | (4.85) | (3.76) | (69.1%) | ||||||
| Cash flow | (234,964.00) | (4,626.18) | (1,690.16) | (1,181.19) | (220.07) | (155.62) | (258.42) | (220.00) | (54.23) | (3.00) | (1.77) | (71.4%) | ||||||
| Capex | (13,499.00) | (226.18) | (28.11) | (2.44) | 0.00 | (1.78) | (5.14) | (2.97) | (0.08) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (248,463.00) | (4,852.36) | (1,718.27) | (1,183.63) | (220.07) | (157.40) | (263.56) | (222.97) | (54.31) | (3.00) | (1.77) | (71.6%) | ||||||
| Book value | (272,590.00) | (11,161.60) | 859.10 | 144.55 | 201.50 | 729.38 | 516.35 | 168.99 | 27.83 | 8.16 | 2.74 | n/m | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 5 | 8 | +235.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 0.00 | 0.00 | 3.09 | 1.84 | 37.83 | 46.11 | 15.01 | 1.89 | 0.71 | 0.29 | 0.42 | 10.7 | ||||||
| P/B | 0.00 | 0.00 | 3.66 | 5.15 | 9.17 | 2.46 | 1.67 | 0.71 | 0.62 | 0.19 | 0.41 | 2.4 | ||||||
| EV/Sales | 0.00 | 0.00 | 2.51 | 3.96 | 36.90 | 33.16 | 11.58 | (0.44) | 0.63 | (0.12) | 0.67 | 8.8 | ||||||
| EV/FCF | (0.69) | (0.69) | (1.49) | (1.36) | (8.17) | (8.20) | (2.53) | 0.12 | (0.28) | 0.21 | (0.98) | (2.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (23) | (21) | (20) | (30) | (38) | (72) | (125) | (125) | (69) | (16) | (20) | (4.0%) | |||||
| Capex | (1) | (1) | 0 | 0 | — | (1) | (2) | (2) | 0 | — | 0 | (27.5%) | ||||||
| Free cash flow | (25) | (22) | (20) | (30) | (38) | (73) | (127) | (127) | (69) | (16) | (20) | (4.5%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 1 | (10) | 19 | 2 | 38 | 251 | 121 | 40 | 2 | 22 | 15 | +36.4% | |||||
| Net debt | 1 | 6 | (7) | 3 | (22) | (247) | (110) | (98) | (17) | (26) | (7) | n/m | ||||||
| Shareholders’ equity | (27) | (50) | 10 | 4 | 35 | 337 | 249 | 96 | 35 | 44 | 32 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (151.19) | (187.43) | (105.85) | (108.40) | (90.68) | (33.11) | (38.74) | (89.09) | (76.97) | (35.13) | (52.04) | +116.1 pt | |||||
| ROIC | 0.00 | 0.00 | (482.56) | (253.19) | (185.94) | (53.45) | (58.86) | 0.00 | (352.46) | (113.43) | (81.68) | (113.4) pt | ||||||
| ROE | 48.65 | 60.31 | 92.27 | (433.64) | (212.46) | (38.92) | (45.21) | (134.56) | (170.33) | (66.15) | (83.56) | (114.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 65 | 77 | 97 | 147 | 299 | 405 | 344 | 100 | 97 | — | +5.1% | |||||
| Revenue/emp, $m | 0.00 | 0.15 | 0.16 | 0.10 | 0.06 | 0.06 | 0.07 | 0.10 | 0.31 | 0.29 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Bionano Genomics, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NEPH Nephros Inc. | $33.6M | 18.0× | 20.2× | +18.01% (above 0%: growing) | +66.67% (above 0%: growing) | −251.52% (below 0%: shrinking) | 58.45% | 8.91% | Compare |
| MLSS Milestone Scientific, Inc. | $27.1M | — (loss-making) | — (loss-making) | +22.27% (above 0%: growing) | n/m | +66.68% (above 0%: growing) | 67.24% | (37.37%) | Compare |
| RVP Retractable Technologies, Inc. | $16.9M | — (loss-making) | 11.1× | −31.07% (below 0%: shrinking) | n/m | +56.67% (above 0%: growing) | 2.65% | (71.46%) | Compare |
| BNGO Bionano Genomics, Inc. | $15.4M | — (loss-making) | — (loss-making) | +21.36% (above 0%: growing) | n/m | −33.93% (below 0%: shrinking) | 52.80% | (88.34%) | |
| NXGL NexGel, Inc. | $12.7M | — (loss-making) | — (loss-making) | +27.81% (above 0%: growing) | n/m | −432.32% (below 0%: shrinking) | 30.09% | (67.96%) | Compare |
| FEMY Femasys Inc. | $11.0M | — (loss-making) | — (loss-making) | −18.93% (below 0%: shrinking) | n/m | +11.29% (above 0%: growing) | 57.08% | (1,526.79%) | Compare |
| CUPR Cuprina Holdings (Cayman) Limited | $10.4M | — | — | — | — | — | — | — | Compare |
| RGNT Regentis Biomaterials Ltd. | $8.2M | — | — | — | — | −132.79% (below 0%: shrinking) | — | — | Compare |
| LUCY Innovative Eyewear, Inc. | $7.2M | — (loss-making) | — | +74.46% (above 0%: growing) | n/m | +9.61% (above 0%: growing) | 24.00% | (168.73%) | Compare |
| Median of peers | $11.8M | — | — | +20.14% | — | +9.61% | 43.58% | (69.71%) |
Pay and ownership Proxy statement filed 2 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.11m | 1.01m | 0.17 |
| 2024 | 989.68k | 535.44k | 1.98 |
| 2023 | 1.53m | (949.35k) | 12.95 |
Ownership
Directors and executive officers, together
0.65%
CVI Investments, Inc.
9.24%
Lind Global Fund III LP
8.65%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement